Table 1 MRN complex protein expression and clinicopathological features in breast cancer.
MRE11 (nuclear) expression | RAD50 (nuclear) expression | NBS1 (nuclear) expression | |||||||
|---|---|---|---|---|---|---|---|---|---|
Low | High | P value | Low | High | P value | Low | High | P value | |
Variable | N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |||
Tumour size | |||||||||
≤2 cm | 150 (42) | 204 (58) | 0.055 | 165 (43) | 217(57) | 0.084 | 223 (44) | 287 (56) | 0.004 |
>2 cm | 152 (49.8) | 153 (50.2) | 174 (50) | 177 (50) | 342 (52) | 314 (48) | |||
Nottingham Prognostic Index (NPI) | |||||||||
1 | 64 (18) | 112 (37) | 84 (58) | 11 9 (34) | 131 (26) | 230 (35) | |||
2 | 217 (61) | 155 (51) | <0.001 | 228 (60) | 184 (52) | 0.001 | 285 (56) | 327 (50) | 0.002 |
3 | 73 (21) | 38 (12) | 70 (18) | 48 (14) | 94 (18) | 99 (15) | |||
Tumour grade | |||||||||
G1 | 27 (8) | 60 (20) | <0.001 | 45 (12) | 61 (17) | <0.001 | 75 (15) | 120 (18) | <0.001 |
G2 | 100 (28) | 127 (42) | 112 (29) | 146 (42) | 148 (29) | 251 (38) | |||
G3 | 226 (64) | 118 (39) | 223 (59) | 144 (41) | 288 (56) | 284 (44) | |||
Mitotic index | |||||||||
M1 (low; mitoses < 10) | 71 (21) | 126 (43) | <0.001 | 88 (24) | 144 (42) | <0.001 | 152 (31) | 240 (38) | 0.002 |
M2 (medium; mitoses 10–18) | 72 (21) | 66 (22) | 80 (22) | 71 (21) | 85 (17) | 131 (21) | |||
M3 (high; mitosis > 18) | 199 (58) | 102 (35) | 198 (54) | 125 (37) | 256 (52) | 260 (41) | |||
Tubule formation | |||||||||
1 (>75% of definite tubule) | 10 (3) | 16 (5) | 0.004 | 11 (3) | 20 (6) | 0.107 | 32 (7) | 33 (5) | 0.547 |
2 (10–75% definite tubule) | 97 (28) | 113 (38) | 120 (33) | 120 (35) | 164 (33) | 224 (36) | |||
3 (<10% definite tubule) | 235 (69) | 165 (56) | 235 (64) | 200 (59) | 197 (60) | 374 (59) | |||
Pleomorphism | |||||||||
1 (small-regular uniform) | 2 (0.6) | 12 (4) | <0.001 | 5 (1) | 9 (3) | 0.063 | 9 (2) | 19 (3) | <0.001 |
2 (moderate variation) | 95 (30) | 128 (44) | 121 (33) | 135 (40) | 154 (31) | 277 (44) | |||
3 (marked variation) | 244 (72) | 154 (52) | 240 (66) | 195 (57) | 329 (67) | 334 (53) | |||
Her2 overexpression | |||||||||
No | 273 (80) | 70 (20) | <0.001 | 310 (84) | 61 (16) | 0.077 | 415 (86) | 67 (14) | 0.525 |
Yes | 269 (91) | 28 (9) | 299 (88) | 40 (12) | 548 (87) | 79 (13) | |||
ER/PR expression status | |||||||||
ER−/PR− | 114 (33) | 45 (15) | <0.001 | 110 (30) | 63 (19) | 0.003 | 148 (30) | 121 (19) | <0.001 |
ER−/PR+ | 0 (0) | 0 (0) | 0 (0) | 1 (0) | 0 (0) | 1 (0) | |||
ER+/PR− | 56 (16) | 47 (16) | 64 (17) | 54 (16) | 80 (16) | 115 (18) | |||
ER+/PR+ | 175 (51) | 204 (69) | 199 (53) | 219 (65) | 260 (53) | 395 (63) | |||
